Guidance

• FY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue progressing in line with the upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of other income received from Regeneron.
• Telix reaffirms R&D expenditure guidance of US$230 million to US$270 million, enabled by the Company’s strong commercial performance and initial payment of US$40 million received from Regeneron.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.